Abstract
MicroRNAs are small noncoding RNAs that have emerged as important regulators of many biological and pathological processes, including those relevant to the development of the heart and cardiovascular disease. Several recent studies using genetic models and profiling of microRNAs have established the important role of these novel molecules in a number of conditions of the heart. These studies have led to a flurry of research focussing on the identification of new therapeutic targets for the treatment of cardiac disease, as well as the identification of potential biomarkers for early diagnosis of heart disease. These early reports have stimulated much interest in microRNAs and indeed other non-coding RNAs in the broader context of cardiovascular disease. This work has been further investigated as a result of ease with which the levels of these molecules can be modulated both in vitro but also in animal disease models. Furthermore, a number of studies have specifically looked at the prognostic potential of these microRNAs as biomarkers of cardiovascular disease. This review is focused on highlighting some of the novel aspects of recent research in the area of the development of new therapeutics and better diagnostics for cardiovascular disease.
Keywords: microRNA, cardiovascular disease, biomarkers.
Current Pharmaceutical Design
Title:microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Volume: 20 Issue: 14
Author(s): Shinji Hagiwara, Phillip Kantharidis and Mark E. Cooper
Affiliation:
Keywords: microRNA, cardiovascular disease, biomarkers.
Abstract: MicroRNAs are small noncoding RNAs that have emerged as important regulators of many biological and pathological processes, including those relevant to the development of the heart and cardiovascular disease. Several recent studies using genetic models and profiling of microRNAs have established the important role of these novel molecules in a number of conditions of the heart. These studies have led to a flurry of research focussing on the identification of new therapeutic targets for the treatment of cardiac disease, as well as the identification of potential biomarkers for early diagnosis of heart disease. These early reports have stimulated much interest in microRNAs and indeed other non-coding RNAs in the broader context of cardiovascular disease. This work has been further investigated as a result of ease with which the levels of these molecules can be modulated both in vitro but also in animal disease models. Furthermore, a number of studies have specifically looked at the prognostic potential of these microRNAs as biomarkers of cardiovascular disease. This review is focused on highlighting some of the novel aspects of recent research in the area of the development of new therapeutics and better diagnostics for cardiovascular disease.
Export Options
About this article
Cite this article as:
Hagiwara Shinji, Kantharidis Phillip and Cooper E. Mark, microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990495
DOI https://dx.doi.org/10.2174/13816128113199990495 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers Associated with Vulnerable Atheromatous Plaque
Current Medicinal Chemistry Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Space Flight Induces Reduction of Paramyosin and Troponin T: Proteomic Analysis of Space-Flown Caenorhabditis elegans
Current Biotechnology Association of Selected Adipocytokines and Inflammatory Markers on Body Mass Index in Type 2 Diabetes Patients in Saudi Arabia and as Risk Factors to Cardiovascular Disease
Current Diabetes Reviews Olive Oil and Apoptosis of Cancer Cells
Current Nutrition & Food Science FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Current Respiratory Medicine Reviews Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety A Review on Pharmacological and Clinical Aspects of Linum usitatissimum L.
Current Drug Discovery Technologies Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Child Abuse and Neglect and its Psycho-Physical and Social Consequences: A Review of the Literature
Current Pediatric Reviews Coronary Atherosclerosis The Implications of Being a Woman
Current Hypertension Reviews Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion
Current Pharmaceutical Design Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design